

MEDICATION SHEET

SCOPE: ALS, CCT				
MEDICATION:	LORAZEPAM (Ativan)			
INTERVENTION:	Classification: Benzodiazepine			
	<u>Actions</u> : Binds highly to the GABA-benzodiazepine receptor complex without displacing GABA. The drug binds to its specific attachment site to improve GABA's attraction to its own receptor site on the GABA-benzodiazepine receptor complex. It exerts tranquilizing action on the central nervous system			
	Contraindications:			
	Hypersensitivity			
	Narrow angle glaucoma			
	Respiratory insufficiency			
	Sleep apnea syndrome			
	Precautions:			
	Concomitant use of alcohol and CNS depressants			
	Hepatic insufficiency			
	Elderly patients			
	Renal failure			
	PREGNANCY RISK FACTOR: D			
	Dosage:			
	I. <u>Seizures:</u>			
	a. Adult			
	i. IV/IO: 1-4 mg, repeat x2			
	 b. Adult High Risk OB hypertensive Disorder i. IV/IO: 4mg slow push, may repeat q 10-15 mins 			
	c. Pediatric			
	i. IV/IO: 0.1 mg/kg (max 4mg), repeat x1			
	II. <u>Anxiolysis</u> :			
	a. Adult:			
	i. IV/IO: 1-2 mg every 30 min PRN			
	 b. Pediatric: i. IV/IO: 0.1 mg/kg every 30 min PRN (max single dose 2 mg) 			
	c. Neonate:			
	i. IV/IO: 0.05-0.1 mg/kg over 5 minutes every 30 min PRN			
	III. <u>Cold Emergencies</u> :			
	a. Adult:			
	i. IV/IO: 1-2mg, repeat as needed			
	Onset of Action: 2-3 minutes			
	Duration: 6-8 hours			
	Adverse Effects: Respiratory depression, apnea, hypotension, dizziness, hyperactive or aggressive behavior			

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

FOR OFFICE US	SE ONLY		
Originator:		Original Date:	
Revised Date:			
Effective Date:	06/01/18		Page 1 of 2

PROTOCOL



Special Considerations: I. N/A